There are three forms of CAPS, familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MES), and neonatal-onset multisystem inflammatory disease (NOMID). FCAS is the mild form of CAPS, MWS is moderate, and NOMID is the most severe form of CAPS.
Common symptoms for all forms of CAPS include (but are not limited to):
- Recurrent fevers
- Joint pain
To learn more about CAPS, here is the Autoinflammatory Alliance information on CAPS and here is the autoinflammatory database.
Studies below include what complications to monitor for, updated research-based effective treatment options, recommended dosing of medications, and other important information for managing and treating CAPS in both children and adults. Only some highlights from each study are included below. For the full study and more comprehensive information, follow the links directly to the study.
In this video, expert Dr. Lachmann of The Royal Free in London discusses CAPS treatment:
“The best diagnosis model included: Raised inflammatory markers (C-reactive protein/serum amyloid A) plus ≥two of six CAPS-typical symptoms: urticaria-like rash, cold-triggered episodes, sensorineural hearing loss, musculoskeletal symptoms, chronic aseptic meningitis and skeletal abnormalities.”
“Early and aggressive treatment for CAPS patients is crucial to avoid end-organ damage. Most CAPS specific symptoms are reversible if treatment is given early…Growth retardation, CNS inflammation and hearing loss have been reported to improve with anakinra in some patients.”
“CAPS disease activity is monitored by the patient’s assessment of disease activity, by a physician’s examination and assessment of judged disease activity, and by examination of inflammatory parameters at defined intervals. As CAPS disease activity may fluctuate, it is important for patients to take notes of their symptoms in a designated diary.”
“Laboratory parameters such as CRP, ESR, and SAA should be monitored.”
“If the skeletal bones are affected, lesions should be monitored on an annual basis. If the CNS is involved, MRI with fluid-attenuated inversion recovery (FLAIR) imaging is recommended and children under five should be monitored by spinal tap and analysis.”
“CAPS patients should be followed by medical centers specialized in the care of patients with auto-inflammatory diseases.”
“Some NLRP3 mutations are present in the general population without essential association to CAPS symptoms, e.g. the V198M or Q703K sequence variants However, when patients carrying these polymorphisms display clinical symptoms, their response to IL-1β inhibition is less favorable, meaning that dosage and frequency of application have to be increased.”
“…use of canakinumab is associated with a persistent satisfactory control of disease activity but needs progressive dose adjustments in more severely affected patients. The clinical phenotype, rather than age, represented the main variable by which the need for more frequent administrations of the drug at a higher dosage was determined.”
“In one study with six NOMID/CINCA patients (aged 11–34 years), patients received 150 mg (2 mg/kg) or 300 mg (4 mg/kg) every 4–8 weeks. A dose increase up to 600 mg (8 mg/kg) was allowed if needed. In 5 out of 6 patients remission was experienced according to patient’s disease activity diaries. However, CRP remained elevated in 1/6 patients and CNS leukocytosis persisted in 5/6 patients…In all patients the canakinumab dose had to be increased to the maximum of 600 mg (8 mg/kg), which however was well tolerated by adults and children alike.”
“Overall, complete response (CR) was seen in 72% of CAPS patients, significantly less often in severe (14%) than in mild CAPS phenotypes (79%). Only 53% attained CR on standard dose canakinumab. Dose increase was more commonly required in children (56%) than in adults (22%). Centres with a treat-to-target approach had significantly higher CR rates (94 vs 50%).”
“Conclusion: Real-life effectiveness of canakinumab in CAPS was significantly lower than in controlled trials. Treat-to-target strategies may improve the outcome of children and adults living with CAPS.”
“For patients with inadequate clinical response or a disease flare, the dose could be increased by 0.5-1 mg/kg for up to a maximum of 10 mg/kg/day.”
“The actual dose range during the study was 0.9-7.6 mg/kg/day, with the highest dose maintained for 15 months followed by a decrease thereafter. The doses were not only increased for preventing disease flares e.g. rash, fever and elevated CRP but also to preserve organ function, e.g. hearing and vision.”
“Anakinra doses were adjusted based on clinical response in order to achieve systemic inflammatory remission and absence of organ inflammation. In one patient doses up to 7.6 mg/kg/day were needed to control CNS inflammation. Dose adjustments were well tolerated with adverse event reporting rates similar in patients on doses <3.5 and ≥3.5mg/kg/day.”
This includes the current recommendations for the treatment and management of cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed by the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE).
“Pneumococcal vaccines can trigger a severe local and systemic inflammatory reaction in patients with CAPS.”
All patients diagnosed with any form of CAPS should discuss this study with their doctors before being vaccinated a pneumococcal vaccine.